Categories: News

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 1:30 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in lupus nephritis and systemic lupus erythematosus without renal involvement, and the CAART (Chimeric AutoAntibody Receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform may offer potentially curative therapies for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

Staff

Recent Posts

Promino Nutritional Sciences Inc. Comments on Trading Halt

Burlington, Ontario--(Newsfile Corp. - May 20, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC…

2 hours ago

SIME Diagnostics Announces Results of Clinical Study on AI-Powered Lung Maturity Test in U.S. Neonatal Intensive Care Unit

LONDON  and ROCHESTER, Minn., May 20, 2025 /PRNewswire/ -- SIME Diagnostics, a UK-based medical technology company…

3 hours ago

New Webinar Empowers Healthcare Organizations to Strengthen Compliance Through Proactive Risk Management

NEW YORK, May 20, 2025 /PRNewswire/ -- With healthcare organizations facing mounting regulatory scrutiny and evolving…

3 hours ago

Zepp Health Corporation Reports First Quarter 2025 Unaudited Financial Results

MILPITAS, Calif., May 19, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE:…

9 hours ago

Community Hospital of Anaconda Notifies Individuals of Data Security Incident

ANACONDA, Mont., May 19, 2025 /PRNewswire/ -- Community Hospital of Anaconda ("CHA") is providing notice…

14 hours ago

Teal Health Announces Publication of SELF-CERV Study Results in JAMA Network Open Following FDA Approval of Teal Wand™ for At-Home HPV Screening

SAN FRANCISCO, May 19, 2025 /PRNewswire/ -- Following its recent FDA approval, Teal Health® announced the…

14 hours ago